Pune, November 12: Serum Institute of India and ICMR, announced the completion of enrolment of phase 3 clinical trials for COVISHIELD in India. ICMR & SII have further collaborated for clinical development of COVOVAX (Novavax) developed by Novavax, USA & upscaled by SII: Serum Institute of India.

Serum Institute, the world’s largest vaccine manufacturer by the number of doses produced, is working on several candidates for a vaccine against coronavirus, including one from AstraZeneca-Oxford University as well as developing its own. COVID-Vaccine Trials in India: Adar Poonawalla, CEO of Serum Institute of India, Urges Media to Refrain From Reporting on Interim Data About Patients on SII-Covishield Clinical Trials.

Serum & ICMR announce the completion of enrollment of phase 3 clinical trials for COVOSHEILD 

Stating that there are no safety concerns related to the Covishield vaccine trial, CEO of Serum Institute, Adar Poonawalla was quoted saying a few days back “It is too early to comment on the vaccine’s availability, or the (chances of) trial completion by December 2020.”

(The above story first appeared on LatestLY on Nov 12, 2020 10:09 AM IST. For more news and updates on politics, world, sports, entertainment and lifestyle, log on to our website latestly.com).